Cerebrospinal fluid biomarkers, education, brain volume, and future cognition.

Knight Alzheimer’s Disease Research Center, St Louis, MO, USA.
Archives of neurology (Impact Factor: 7.58). 09/2011; 68(9):1145-51. DOI: 10.1001/archneurol.2011.192
Source: PubMed

ABSTRACT Cross-sectional studies suggest that the cognitive impact of Alzheimer disease pathology varies depending on education and brain size.
To evaluate the combination of cerebrospinal fluid biomarkers of β-amyloid(42) (Aβ(42)), tau, and phosphorylated tau (ptau(181)) with education and normalized whole-brain volume (nWBV) to predict incident cognitive impairment.
Longitudinal cohort study.
Charles F. and Joanne Knight Alzheimer's Disease Research Center, Washington University, St Louis, Missouri.
A convenience sample of 197 individuals 50 years and older with normal cognition (Clinical Dementia Rating of 0) at baseline observed for a mean of 3.3 years.
Time to Clinical Dementia Rating ≥ 0.5.
Three-factor interactions among the baseline biomarker values, education, and nWBV were found for Cox proportional hazards regression models testing tau (P = .02) and ptau (P = .008). In those with lower tau values, nWBV (hazard ratio [HR], 0.54; 95% confidence interval [CI], 0.31-0.91; P = .02), but not education, was related to time to cognitive impairment. For participants with higher tau values, education interacted with nWBV to predict incident impairment (P = .01). For individuals with lower ptau values, there was no effect of education or nWBV. Education interacted with nWBV to predict incident cognitive impairment in those with higher ptau values (P = .02).
In individuals with normal cognition and higher levels of cerebrospinal fluid tau and ptau at baseline, time to incident cognitive impairment is moderated by education and brain volume as predicted by the cognitive/brain reserve hypothesis.

1 Bookmark
  • [Show abstract] [Hide abstract]
    ABSTRACT: The anticipated rise of dementia prevalence due to global aging may be tackled by morbidity compression through lifestyle changes (i.e., consistent participation in physical and intellectual activities) that promote cognitive reserve. A hypothetical model of cognitive decline due to Alzheimer's disease (AD) and modulation of the clinical trajectory by cognitive reserve is presented. People with higher cognitive reserve are expected to show delay of the mild cognitive impairment phase but faster conversion to AD thereafter. Once conversion to AD is evident, there would be even faster deterioration, resulting in compression of morbidity. When morbidity is compressed, not only is prevalence reduced but the caregiving load is also compressed; this is referred to as "double compression." Research and policy directions are discussed.
    The Gerontologist 03/2014; · 2.48 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Graph theory models can produce simple, biologically informative metrics of the topology of resting-state functional connectivity (FC) networks. However, typical graph theory approaches model FC relationships between regions (nodes) as unweighted edges, complicating their interpretability in studies of disease or aging. We extended existing techniques and constructed fully connected weighted graphs for groups of age-matched human immunodeficiency virus (HIV) positive (n = 67) and HIV negative (n = 77) individuals. We compared test-retest reliability of weighted versus unweighted metrics in an independent study of healthy individuals (n = 22) and found weighted measures to be more stable. We quantified 2 measures of node centrality (closeness centrality and eigenvector centrality) to capture the relative importance of individual nodes. We also quantified 1 measure of graph entropy (diversity) to measure the variability in connection strength (edge weights) at each node. HIV was primarily associated with differences in measures of centrality, and age was primarily associated with differences in diversity. HIV and age were associated with divergent measures when evaluated at the whole graph level, within individual functional networks, and at the level of individual nodes. Graph models may allow us to distinguish previously indistinguishable effects related to HIV and age on FC.
    Neurobiology of aging. 06/2014;
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Alzheimer disease (AD) is a complex neurodegenerative disorder, whose prevalence will dramatically rise by 2050. Despite numerous clinical trials investigating this disease, there is still no effective treatment. Many trials showed negative or inconclusive results, possibly because they recruited only patients with severe disease, who had not undergone disease-modifying therapies in preclinical stages of AD before severe degeneration occurred. Detection of AD in asymptomatic at risk individuals (and a few presymptomatic individuals who carry an autosomal dominant monogenic AD mutation) remains impractical in many of clinical situations and is possible only with reliable biomarkers. In addition to early diagnosis of AD, biomarkers should serve for monitoring disease progression and response to therapy. To date, the most promising biomarkers are cerebrospinal fluid (CSF) and neuroimaging biomarkers. Core CSF biomarkers (amyloid β1-42, total tau, and phosphorylated tau) showed a high diagnostic accuracy but were still unreliable for preclinical detection of AD. Hence, there is an urgent need for detection and validation of novel CSF biomarkers that would enable early diagnosis of AD in asymptomatic individuals. This article reviews recent research advances on biomarkers for AD, focusing mainly on the CSF biomarkers. In addition to core CSF biomarkers, the potential usefulness of novel CSF biomarkers is discussed.
    Croatian Medical Journal 08/2014; 55(4):347-365. · 1.25 Impact Factor


Available from
Jun 4, 2014